Cite
HARVARD Citation
Santoni-Rugiu, E. et al. (2017). Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Lung cancer. pp. 14-17. [Online].